---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-128266"
form_type: "8-K"
ticker: "CYTK"
cik: "0001061983"
company_name: "CYTOKINETICS INC"
filed_at: "2024-11-19T23:59:59+00:00"
generated_at: "2026-05-29T22:17:48.471395+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cytokinetics licenses aficamten Japan rights to Bayer for €50M upfront, up to €580M milestones

## Summary
- Upfront payment of €50 million from Bayer; additional clinical/commercial launch milestones up to €90 million.
- Commercial milestone payments up to €490 million based on net sales thresholds.
- Tiered royalties on Japan net sales ranging from high-teens to low-thirty percent.
- Bayer responsible for development and commercialization at its own cost; Cytokinetics retains rights to ACACIA-HCM and CEDAR-HCM trials in Japan.

## SEC filing metadata
- accession: 0000950170-24-128266
- form_type: 8-K
- ticker: CYTK
- cik: 0001061983
- company_name: CYTOKINETICS INC
- filed_at: 2024-11-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061983/000095017024128266/0000950170-24-128266-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061983/000095017024128266/cytk-20241118.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-128266
- JSON: https://secwatch.observer/filing/0000950170-24-128266.json
- Plain text: https://secwatch.observer/filing/0000950170-24-128266.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.